Why Alnylam Pharmaceuticals Bears Were Right Before A 65% Drop

If you backed Alnylam Pharmaceuticals on its RNAi promise and expanding ATTR-CM market back in November 2025, the outcome has been brutal. For Alnylam Pharmaceuticals shareholders, the loss over the past year was 64.6%, including dividends. If you had bought on the idea of rapid AMVUTTRA uptake, structurally higher profitability and a bigger patient pool from demographic aging, which of those specific assumptions failed to anticipate what actually unfolded?

On Simply Wall St, a Narrative is an investor's thesis written down: the reasoning, plus the numbers it rests on. Run those numbers and you get an estimated Fair Value.

The move put Alnylam Pharmaceuticals in the middle of this trade. Scan 34 healthcare AI stocks for other companies exposed to it.

The Argument You Would Have Been Weighing Up On Alnylam Pharmaceuticals

Alnylam Pharmaceuticals shares cost US$435 at the start of the period. Anyone buying then had to choose between two very different stories that both sounded plausible based on what was known.

The bullish Narrative pinned Fair Value at US$559, or 29% above the start price. That view leaned on assumptions about rapid AMVUTTRA uptake, majority market share in ATTR-CM, and structurally higher profitability supported by advances in RNAi and high-prevalence indications.

The bearish Narrative put Fair Value at US$236, or 46% below the start price. That camp focused on dependence on the TTR franchise, pricing pressure on AMVUTTRA, and the risk that high R&D and SG&A spending kept margins compressed even if adoption stayed strong.

What The Evidence Did To The Alnylam Pharmaceuticals Argument

The clearest test of the Alnylam Pharmaceuticals story came from its Q3 2026 report. Revenue reached US$1,458.086 million and net income was US$2,167.335 million, with net margin very large at 148.6%. That supported the profitability part of the optimistic case, even if one quarter is not enough to judge durability.

The lesson is about what you watch. The bullish pitch hinged on structurally higher profitability. The key check elsewhere is simple: track net margin over several reports and compare it with management’s own guidance, not just headline revenue or short term share moves.

What You Are Paying For In Alnylam Pharmaceuticals After A 65% Fall

Alnylam Pharmaceuticals now trades at US$157. This Narrative’s Fair Value sits above that level based on its own assumptions rather than objective fact.

The current bullish Narrative leans on RNAi breadth and TTR execution as the drivers that could make the drawdown an opening instead of a warning, if you believe those franchises can deliver.

"The broad RNAi portfolio at Alnylam Pharmaceuticals, with more than 25 programs across rare, specialty and prevalent conditions and multiple pivotal studies underway, creates repeated opportunities for new approvals that could add incremental revenue streams and help spread fixed R&D and SG&A over a larger sales base, which may support earnings."

The price and this Narrative do not agree. → Uncover what this Narrative says Alnylam Pharmaceuticals is actually worth

How Could You Get There Earlier?

Passing on this one could have spared you a loss. Where might you find the opposite surprise? Start looking for companies whose prices leave room for a better outcome than investors expect. These three trade below our estimated value.

• Company 1 - 24% below our estimate - targets electrical projects tied to electrification, data centers and offshore energy buildouts.
• Company 2 - 23% below our estimate - supplies wet cleaning and advanced packaging tools as chipmakers shift to larger, complex designs.
• Company 3 - 39% below our estimate - expands a dense, app-driven store network as more customers order coffee through mobile channels.

Three companies from the same screener. Open all 42 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com